Kalorama Vaccine Market Research Report Bundle (Vaccines 2012, What's Next in Vaccines, Vaccine Production Markets)

 
   Single User - $3,995
   Site License (one location, 10 users) - $5,995
   Corporate License - $7,990


Loading...
Published Oct 18, 2012 | 700 Pages | Pub ID: KLI4891982

Vaccines are an important part of the business model of top pharmaceutical companies. The success of several recent vaccine product introductions has been of great interest to pharma R&D efforts. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth in many categories through 2011, declines in others, and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.

What vaccines are on the market and how much are they earning for manufacturers?  What revenues will be seen in the next five years?  What diseases are likely to be treated with vaccine products in the future?  What will those new products add to the market on top of existing vaccines?  How does the vaccine industry currently work, and what do new entrants have to know to enter the marketplace? What trends are driving and limiting growth? Who are the key players in the industry, and new entrants?  How much are vaccine companies spending on production?  These questions and more are answered in a unique Kalorama Information market research report bundle.  

This Kalorama Vaccine Market Research Report Bundle combines three comprehensive reports on different aspects of the vaccine industry bundled in one PDF, allowing our clients to stretch their market research dollars.

  • Vaccines 2012 (Published September 2012)  A complete review of the vaccine market in 2012 including adult and pediatric vaccines.  Market sizes and forecasts are provided for Pediatric (Combinations, Hepatitis, HIB, MMR, Pneumococcal, Poliovirus, Varicella  Other Pediatric), as well as adult vaccines (Cervical Cancer, Hepatitis, Influenza, Pneumococcal, Travel; DT; Misc.)
  • What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)  (Published June  2012) This report  examines and estimates the market for vaccines that have yet to be launched. What diseases may see a prophylactics vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market?
  • Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts) (Published February 2012) This report,  examines the market for vaccine manufacturing and production technologies. The focus is on current production methods and new methods in development. While there may be some overlap for technologies in development, the emphasis of the report is process rather than product development.

At over 600 pages, this Market Research Bundle provides a tremendous value to customers who are interested in knowing the all of the key trends, expected future products, most important competitors and costs of production in the vaccine industry.  As with all Kalorama Information reports, the complete market research studies combine secondary research and company reports with primary research interviews.  

Companies covered in this report bundle include:
  • Affiris
  • Alk-Abello A/S
  • Allergy Therapeutics
  • AstraZeneca
  • Bavarian Nordic A/S
  • Baxter Healthcare
  • Cytos Biotechnology
  • GlaxoSmithKline
  • Hawaii Biotech
  • Mymetics
  • Nabi Biopharmaceuticals
  • Opexa Therapeutics
  • Sanofi Pasteurc
  • AlphaVax, Inc.
  • Bharat Biotech
  • Merck & Co. Inc
  • Crucell /Johnson & Johnson
  • Emergent biosolutions
  • Novartis
  • Pfizer
  • Merck KgaA
  • Novartis AG
  • Teva
  • CSL Biotherapies
  • Intercell
  • MedImmune/Astra Zeneca
  • MassBioLogics
  • Lonza
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnology
  • Catalent Pharma Solutions
  • Patheon
  • DSM Pharmaceutical
  • IDT Biologika
  • Charles River Biopharmaceutical Services (BPS)
VACCINE MARKET RESEARCH BUNDLE INCLUDES THREE SEPARATE REPORTS IN ONE PDF:


VACCINES 2012
-----------------------------------

CHAPTER ONE: EXECUTIVE SUMMARY
  • The Global Vaccine Industry
    • Scope and Methodology
    • Overview
    • Pediatric Preventative Vaccines
    • The Market
    • Adult Preventative Vaccines
    • The Market
    • Total Market
    • Issues and Trends
CHAPTER TWO: INTRODUCTION TO VACCINES
  • A Brief History: The Development of Vaccines
  • The Immune Response
  • Mechanism of Action
  • Types of Vaccines
    • Attenuated (Weakened) Live Viruses
    • Killed (Inactivated) Viruses
    • Toxoid Vaccines
    • Genetically Engineered/Modified Vaccines
    • Vaccine Approval Process
CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES
  • Introduction
  • Childhood Immunization in the United States
    • Childhood Immunization Rates
    • Challenges to the Vaccine Delivery System
    • The Effect of U.S. Healthcare Reform
    • Recommended Childhood Immunization Schedule
    • State Immunization Recommendations
    • United Nations Initiatives
  • Pediatric Vaccine Products
    • BCG
    • Diphtheria, Tetanus, Pertussis, Hepatitis B and Polio
    • Haemophilus Influenzae Type B
    • Hepatitis A
    • Measles, Mumps and Rubella
    • Meningococcal Disease
    • Pneumococcal Conjugate
    • Rotavirus
    • Varicella
  • Pediatric Vaccines in Development
  • Cost of Vaccines in the United States
  • The World Market for Pediatric Preventive Vaccines
    • Total Market Size and Forecast
    • Hepatitis Vaccine Market
    • Haemophilus Influenzae Type B Vaccine Market
    • Measles, Mumps and Rubella Vaccines
    • Combination Vaccines Market
    • Pneumococcal Vaccine
    • Poliovirus Vaccine
    • Varicella Vaccines
    • Other Vaccines Market
CHAPTER FOUR: ADULT PREVENTIVE VACCINES
  • Introduction
  • Adult Vaccine-Preventable Diseases: Facts and Figures
  • Global Influenza Surveillance Program
    • U.S. Surveillance
    Recommendations for Adult Immunizations
    • WHO International Health Regulations
  • Adult Vaccine Products
    • Cervical Cancer
    • Cholera
    • Diphtheria-Tetanus
    • Hepatitis
    • Influenza
    • Japanese Encephalitis
    • Pneumococcal Disease
    • Rabies
    • Shingles
    • Typhoid Fever
    • Yellow Fever
  • Adult Vaccines in Development
  • The World Market for Adult Preventive Vaccines
    • Total Market Size and Forecast
    • Cervical Cancer Market
    • Hepatitis Market
    • 1Influenza Vaccine Market
    • Travel, DT, and Miscellaneous Vaccine Market
CHAPTER FIVE: VACCINES MARKET SUMMARY
  • Trends Driving the Vaccines Market
  • Market Size and Forecast
  • Vaccine Sales by Region
  • Vaccine Market Competitors
  • Pediatric Vaccines
  • Adult Vaccines
CHAPTER SIX: ISSUES AND TRENDS
  • Vaccine Safety
  • Refusal to Immunize
  • Obesity
  • Post-Licensure Surveillance
  • The Vaccine Injury Compensation Program
  • World Health Organization
  • Other Initiatives
  • The Future of Vaccine Safety
  • Vaccine Shortages
  • Preventing Shortages in the Developed Countries
  • Preventing Shortages in Developing Nations
  • Preventing Pandemics
  • U.S. National Vaccine Plan
  • Vaccines and Bioterrorism
  • Overview
  • Project Bioshield Act
  • National Bio and Agro-Defense Facility
  • Vaccine Treatment and Evaluation Units
  • Anthrax
  • Smallpox
  • DNA Vaccination
  • Innovations in Vaccine Delivery Systems
  • Mucosal Delivery
  • Intranasal Delivery
  • Vaccine Patches
  • Vaccine Chips and Microneedles
  • Innovations in Vaccine Production
  • Plants
  • Insects
  • Nanoparticle Systems
  • Cloning
CHAPTER SEVEN: COMPANY PROFILES
  • AlphaVax, Inc.
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Bavarian Nordic A/S
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Baxter Healthcare
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Bharat Biotech
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Crucell /Johnson & Johnson
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Emergent biosolutions
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial
  • GlaxoSmithKline
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Medimmune
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Merck & Co. Inc
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Novartis
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Sanofi Pasteur
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
APPENDIX: COMPANY DIRECTORY

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Figure 1-1: World Market for Pediatric Vaccines 2007-2016 Revenues (in millions)
  • Figure 1-2: World Market for Adult Vaccines 2007-2016 Revenues (in millions)
CHAPTER TWO: INTRODUCTION TO VACCINES
    Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2011
  • Exhibit 2-1: Attenuated Virus Production
  • Table 2-2: Vaccine-Preventable Diseases, August 2012
  • Table 2-3: VAERS Table of Reportable Events Following Vaccination
CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES
    Table 3-1: Global Immunization Rates by Vaccine Type 2010
  • Table 3-2: Immunization Profile of the United States: Population by Age Group, Number of Vaccine-Preventable Diseases Reported by Disease 1990 - 2010
  • Table 3-3: U.S. Recommended Immunization Schedule for Children Ages 0 Through 6 Years, 2012
  • Table 3-4: U.S. Recommended Immunization Schedule for Adolescents Age 7 to 18 Years, 2012
  • Table 3-5: Selected Pediatric Vaccines in Development, August 2012
  • Table 3-6: World Market for Pediatric Vaccines by Type (DTaP/DTP, Hep, HiB, MMR, Combinations, Pneumococcal, Polio, Varicella, Others) 2007-2016 Revenues (in millions)
  • Figure 3-1: Market Share of Pediatric Vaccines by Type 2011
  • Figure 3-2: Market Share of Pediatric Vaccines, by Type 2016
  • Table 3-7: World Market for Pediatric Vaccines by Region (U.S., North America, South America, EU, Japan, India, China, Rest of World) 2006-2015 Revenues
  • Table 3-8: World Pediatric Hepatitis Vaccine Market 2007-2016
  • Table 3-9: World Hib Vaccine Market, 2007-2016
  • Table 3-10: World MMR Vaccines Market 2007-2016
  • Table 3-11: World Combination Vaccines Market 2007-2016
  • Table 3-12: World Pediatric Pneumococcal Vaccine Market 2007-2016
  • Table 3-13: World Poliovirus Vaccine Market 2007-2016
  • Table 3-14: World Varicella Vaccine Market 2007-2016
  • Table 3-15: World Pediatric Other Vaccines Market 2007-2016
CHAPTER FOUR: ADULT PREVENTIVE VACCINES
  • Table 4-1: Universal Adult Immunization Schedule 2012
  • Table 4-2: Summary of Recommendations for Adult Immunization
  • Table 4-3: Initiatives to Require HPV Vaccination by U.S. State, 2012
  • Figure 4-1: U.S. Flu Season Severity from 2002 to 2012
  • Table 4-4: WHO Pandemic Classification Schedule
  • Table 4-5: Selected Adult Preventive Vaccines in Development, 2012
  • Table 4-6: World Market for Adult Preventive Vaccines by Type (Hepatitis, Influenza, Pneumococcal, Travel/DT/Misc.), 2007-2016 Revenues
  • Figure 4-1: Market Share of Adult Vaccines, by Type, 2011
  • Figure 4-2: Market Share of Adult Vaccines, by Type, 2016
  • Table 4-7: World Market for Adult Vaccines by Region (U.S., North America, South America, EU, Japan, India, China, Rest of World) 2007-2016 Revenues
  • Table 4-8: World Cervical CancerVaccine Market 2007-2016
  • Table 4-9: World Hepatitis Vaccine Market 2007-2016
  • Table 4-10: World Influenza Vaccine Market 2007-2016
  • Table 4-11: 2011 Estimated Population by Region and Selected Age Group
  • Table 4-12: World Pneumococcal Vaccine Market 2007-2016
  • Table 4-13: World Travel; Diphtheria-Tetanus; Miscellaneous Vaccines Market 2007-2016
CHAPTER FIVE: VACCINES MARKET SUMMARY
    Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals 2007-2016
  • Table 5-1: The World Vaccines Market by Vaccine Type 2007-2016 Revenues
  • Figure 5-2: World Market for Vaccines Share by Type, 2007, 2011 and 2016
  • Table 5-2: The World Vaccines Market by Region (U.S., North America, SouthAmerica, EU, Japan, India, China, ROW) 2007-2016 Revenues
  • Table 5-3: Major Manufacturers’ Shares of the World Vaccine Market, 2011
  • Figure 5-3: 2011 World Vaccines Market Share, by Leading Competitors
  • Table 5-4: Major Manufacturer’s Shares of the World Pediatric Vaccine Market 2011
  • Figure 5-5: Market Share of Pediatric Vaccines Market, 2011
  • Table 5-5: Major Manufacturer’s Shares of the World Adult Vaccine Market 2011
  • Figure 5-6: Market Share of Adult Vaccines Market 2011
CHAPTER SIX: ISSUES AND TRENDS
    Table 6-1: Selected Companies/Laboratories Developing Biodefense Vaccines

WHAT'S NEXT IN VACCINES

----------------------------------------

CHAPTER ONE: EXECUTIVE SUMMARY

  • Emerging Vaccines
    • Scope and Methodology
    • Overview
    • Emerging Vaccines and Forecasts
    • The Global Market for Emerging Vaccines
CHAPTER TWO: INTRODUCTION TO VACCINES
  • A Brief History: The Development of Vaccines
  • The Immune Response
  • Mechanism of Action
  • Types of Vaccines
    • Attenuated (Weakened) Live Viruses
    • Killed (Inactivated) Viruses
    • Toxoid Vaccines
    • Genetically Engineered/Modified Vaccines
    • Bacteria-Based Vaccines
  • Vaccine Approval Process
  • Refusal to Immunize
  • Expanding Vaccine Availability
  • Other Trends Driving the Vaccines Market
CHAPTER THREE: EMERGING VACCINES
  • Introduction
  • Emerging Vaccines by Disease Area
    • Acne
    • Addiction
    • Allergy
    • Alzheimer’s Disease
    • Anthrax
    • Asthma
    • Campylobacter Infection
    • Chlamydia
    • Croup
    • Cytomegalovirus (CMV)
    • Dengue Fever
    • Diabetes
    • Ebola
    • Epstein-Barr Virus
    • Enterotoxigenic Escherichia coli (ETEC
    • Heart Attack
    • Helicobacter Pylori
    • Hepatitis
    • Herpesvirus
    • Hookworm
    • Hypertension
    • HIV/AIDS
    • Leishmaniasis
    • Malaria
    • MRSA Infection
    • Multiple Sclerosis
    • Obesity
    • Parainfluenza Virus Type 3
    • Parkinson’s Disease
    • Plague
    • Ross River Virus
    • Shigellosis
    • Stroke
    • Tuberculosis
    • West Nile Virus
CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST
  • the Global Market for Emerging Vaccines
  • Emerging Vaccines Market Segment Forecasts
    • Acne
    • Addiction
    • Allergies
    • Alzheimer’s Disease
    • Anthrax
    • Asthma
    • Campylobacter Infection
    • Celiac Disease
    • Chlamydia
    • Croup
    • Diabetes
    • Ebola
    • EBV Infection
    • ETEC Infection
    • Heart Attack
    • H. Pylori Infection
    • Hepatitis C and E
    • Herpesvirus Infection
    • Hookworm
    • Hypertension
    • HIV/AIDS
    • Leishmaniasis
    • Malaria
    • MRSA Infection
    • Multiple Sclerosis
    • Obesity
    • PIV-3 Infection
    • Parkinson’s Disease
    • Plague
    • RSV Infection
    • Ross River Virus Infection
    • Shigellosis
    • Stroke
    • Tuberculosis
    • West Nile Virus
CHAPTER FIVE: ISSUES AND TRENDS
  • New Vaccine Delivery System
    • Edible Vaccines
    • Mucosal Delivery
    • Intranasal Delivery
    • Vaccine Patches
  • Funding Shortfalls
  • Project Terminations
CHAPTER SIX: COMPANY PROFILES
  • Affiris
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Alk-Abello A/S
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Allergy Therapeutics
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • AstraZeneca
    • History and Lines of Business
    • Emerging Vaccine Products
    • Financial Information
  • Bavarian Nordic A/S
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Baxter Healthcare
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Crucell
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Cytos Biotechnology
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial
  • GlaxoSmithKline
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Hawaii Biotech
    • History and Lines of Business
    • Emerging Vaccine Products
    • Financial Information
  • Merck & Co. Inc
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Mymetics
    • History and Lines of Business
    • Emerging Vaccine Products
    • Financial Information
  • Nabi Biopharmaceuticals
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Novartis
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Opexa Therapeutics
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Sanofi Pasteur
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
    APPENDIX: COMPANY DIRECTORY

CHAPTER ONE: EXECUTIVE SUMMARY
  • Table 1-1: Status of Emerging Vaccines by Disease
CHAPTER TWO: INTRODUCTION TO VACCINES
  • Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2011
  • Table 2-2: Vaccine-Preventable Diseases, December 2011
  • Figure 2-1: Attenuated Virus Production
  • Table 2-3: VAERS Table of Reportable Events Following Vaccination
CHAPTER THREE: EMERGING VACCINES
  • Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines, 2012
  • Figure 3-2: Comparative Mortality, Symptom Severity and Treatment Availability for Conditions Addressed by Emerging Vaccines
  • Table 3-1: Emerging Vaccines by Disease and Stage of Testing
  • Figure 3-3: Comparative Severity Ranking of Acne
  • Figure 3-4: Comparative Severity Ranking of Addiction
  • Figure 3-5: Comparative Severity Ranking of Allergy
  • Figure 3-6: Comparative Severity Ranking of Alzheimer’s Disease
  • Figure 3-7: Comparative Severity Ranking of Anthrax
  • Figure 3-8: Comparative Severity Ranking of Asthma
  • Figure 3-9: Comparative Severity Ranking of Campylobacter Infection
  • Figure 3-10: Comparative Severity Ranking of Celiac Disease
  • Figure 3-11: Comparative Severity Ranking of Chlamydia
  • Figure 3-12: Comparative Severity Ranking of Croup
  • Figure 3-13: Comparative Severity Ranking of Cytomegalovirus
  • Figure 3-14: Comparative Severity Ranking of Dengue Fever
  • Figure 3-15: Comparative Severity Ranking of Diabetes
  • Figure 3-16: Comparative Severity Ranking of Ebola
  • Figure 3-17: Comparative Severity Ranking of EBV
  • Figure 3-18: Comparative Severity Ranking of ETEC
  • Figure 3-19: Comparative Severity Ranking of Heart Attack
  • Figure 3-20: Comparative Severity Ranking of H. Pylori Infection
  • Figure 3-21: Comparative Severity Ranking of Hepatitis C and E
  • Figure 3-22: Comparative Severity Ranking of Herpesvirus Infection
  • Figure 3-23: Comparative Severity Ranking of Hookworm
  • Figure 3-24Comparative Severity Ranking of Hypertension
  • Figure 3-25: Comparative Severity Ranking of HIV/AIDS
  • Figure 3-26: Comparative Severity Ranking of Leishmaniasis
  • Figure 3-27: Comparative Severity Ranking of Malaria
  • Figure 3-28: Comparative Severity Ranking of MRSA Infection
  • Figure 3-29: Comparative Severity Ranking of Multiple Sclerosis
  • Figure 3-30: Comparative Severity Ranking of Obesity
  • Figure 3-31: Comparative Severity Ranking of PIV-3 Infection
  • Figure 3-32: Comparative Severity Ranking of Parkinson’s Disease
  • Figure 3-33: Comparative Severity Ranking of Plague
  • Figure 3-34: Comparative Severity Ranking of RSV Infection
  • Figure 3-35: Comparative Severity Ranking of Ross River Virus Infection
  • Figure 3-36: Comparative Severity Ranking of Shigellosis
  • Figure 3-37: Comparative Severity Ranking of Stroke
  • Figure 3-38: Comparative Severity Ranking of Tuberculosis
  • Figure 3-39: Comparative Severity Ranking of West Nile Virus Infection
CHAPTER FOUR: MARKET ANALYSIS
  • Table 4-1:World Market for Emerging Vaccines by Type, 2011
  • Table 4-2: World Market for Emerging Vaccines by Type, 2011-2021
  • Table 4-3: World Acne Vaccine Market 2011-2021
  • Table 4-4: World Addiction Vaccine Market 2011-2021
  • Table 4-5: World Allergy Vaccine Market 2011-2021
  • Table 4-6: World Alzheimer’s Disease Vaccine Market 2011-2021
  • Table 4-7: World Anthrax Vaccine Market 2011-2021
  • Table 4-8: World Asthma Vaccine Market 2011-2021
  • Table 4-9: World Campylobacter Vaccine Market 2011-2021
  • Table 4-10: World Celiac Disease Vaccine Market 2011-2021
  • Table 4-11: World Chlamydia Vaccine Market 2011-2021
  • Table 4-12: World Croup Vaccine Market 2011-2021
  • Table 4-13: World Cytomegalovirus Vaccine Market 2011-2021
  • Table 4-14: World Dengue Fever Vaccine Market 2011-2021
  • Table 4-15: World Diabetes Vaccine Market 2011-2021
  • Table 4-16: World Ebola Vaccine Market 2011-2021
  • Table 4-17: World EBV Vaccine Market 2011-2021
  • Table 4-18: World ETEC Vaccine Market 2011-2021
  • Table 4-19: World Heart Attack Vaccine Market 2011-2021
  • Table 4-20: World H. Pylori Vaccine Market 2011-2021
  • Table 4-21: World Hepatitis C & E Vaccine Market 2011-2021
  • Table 4-22: World Herpesvirus Vaccine Market 2011-2021
  • Table 4-23: World Hookworm Vaccine Market 2011-2021
  • Table 4-24: World Hypertension Vaccine Market 2011-2021
  • Table 4-25: World HIV/AIDS Vaccine Market 2011-2021
  • Table 4-26: World Leishmaniasis Vaccine Market 2011-2021
  • Table 4-27: World Malaria Vaccine Market 2011-2021
  • Table 4-28: World MRSA Vaccine Market 2011-2021
  • Table 4-29: World Multiple Sclerosis Vaccine Market 2011-2021
  • Table 4-30: World Obesity Vaccine Market 2011-2021
  • Table 4-31: World PIV-3 Vaccine Market 2011-2021
  • Table 4-32: World Parkinson’s Disease Vaccine Market 2011-2021
  • Table 4-33: World Plague Vaccine Market 2011-2021
  • Table 4-34: World RSV Vaccine Market 2011-2021
  • Table 4-35: World Ross River Virus Vaccine Market 2011-2021
  • Table 4-36: World Shigellosis Vaccine Market 2011-2021
  • Table 4-37: World Stroke Vaccine Market 2011-2021
  • Table 4-38: World Tuberculosis Vaccine Market 2011-2021
  • Table 4-39: World West Nile Virus Vaccine Market 2011-2021

 


VACCINE PRODUCTION MARKETS

---------------------------------------------

CHAPTER ONE: EXECUTIVE SUMMARY

    Scope and Methodology
  • Production Technology
    • Legacy Technologies
    • Innovative Technologies
  • Manufacturing
    • Originator and Big Pharma
    • Contract Manufacturing Organizations
  • Profitability of The Vaccine Industry
  • Major Vaccine Manufacturers
  • Conclusions
  • Scope and Methodology
CHAPTER TWO: THE VACCINE INDUSTRY: TRENDS, MAJOR PLAYERS AND MARKETS
    Overview
  • Types of Vaccines
    • Attenuated (Weakened) Live Viruses
    • Killed (Inactivated) Viruses
    • Toxoid Vaccines
    • Genetically Engineered/Modified Vaccines
    • Subunit Vaccines
    • Conjugate Vaccines
    • DNA Vaccination
  • Major Vaccine Manufacturers
  • Vaccine Approval Process
    • Government and NGO Investment
    • Manufacturing and Infrastructure Building
    • Centers for Innovation in Advanced Development and Manufacturing
    • BARDA Influenza & Emerging Disease Program
    • WHO
  • The cycle of Vaccine Procurement
  • Public/Private Partnerships
    • Bush Administration/Homeland Security
    • Project GreenVax
    • Vaccine Research Center Production Programs
  • Production, Prices and Other Profit Considerations
    • Negotiated Prices
    • Production Expenses
    • Sales and Marketing Expenses
CHAPTER THREE: VACCINE PRODUCTION: SPENDING, INNOVATIONS, AND CHALLENGES
    Vaccine Production Estimates
  • Main Vaccine Types
    • Inactivated Vaccines or Live attenuated vaccines
    • Acellular / Component Vaccines
    • Live, Attenuated Vaccines
    • Toxoid Vaccines
    • Analogue Vaccines
    • Vaccines through Genetic Engineering
  • Reformulation
    • Thiomersal
  • Influenza Vaccine Production
  • Influenza Vaccine Production
    • Egg Production
    • Unique Aspects of Manufacturing Influenza Vaccine
    • Rate-Limiting Steps in the Seasonal Vaccine Process
    • Cellular Production
  • WHO Annual Flu Vaccine Guidelines
  • Pandemics
  • History and Shortages
  • HIN Pandemic of /
  • The Vaccine Industry's Role
  • A Decade of Pandemic Preparations
  • WHO Pandemic Influenza Vaccine Manufacturing Process and Timeline
  • Activities at regulatory agencies - regulatory approval
  • Mammalian Cell Culture
  • Background
  • Cell - Mammalian
  • Cell Culture Influenza Vaccines
  • Advantages
  • Ideal cell lines for production
  • Specific Cell Lines
  • Madin Darby Canine Kidney (MDCK)
  • Vero Cells
  • PER.C cells
  • DNA Vaccines
  • Concerns
  • Novartis and Medicago Open Non-Traditional Vaccine Operations
  • Vaccine Distribution
  • Estimates of Vaccine Production Spending
  • Contract Vaccine Manufacturing
  • Contract Manufacturing Market
CHAPTER FOUR: COMPANY PROFILES
    GlaxoSmithKline Biopharmaceuticals
  • Sanofi-Aventis
  • Merck KgaA
  • Pfizer-Pfizer CenterSource
  • Novartis AG
  • Baxter International
  • Teva
  • Crucell (Johnson &Johnson)
  • CSL Biotherapies
  • Intercell
  • MedImmune/Astra Zeneca
  • MassBioLogics
CHAPTER FIVE: VACCINE CONTRACT MANUFACTURERS
    Lonza
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnology
  • Fujifilm Diosynth Biotechnology
  • Catalent Pharma Solutions
  • Patheon
  • DSM Pharmaceutical
  • Cambrex (Lonza)
  • IDT Biologika
  • Charles River Biopharmaceutical Services (BPS)

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: The Major Vaccine Development Categories

  • Table 1-2: World Vaccines Market (Pediatric and Adult)

  • Table 1-3: Technologies with the Greatest Promise for Producing Vaccines, 2011

  • Figure 1-1: Vaccine Industry Production Spending, 2008-2015

  • Figure 1-2: Discount for Selected Vaccines (ActHIB, Havrix, Tripedia, Fluarix, FluMist, Twinrix, Afluria, Decavac, MMRII, Zostravix, ENGERIX-B, Ceravix, Gardasil, Prevnar)

  • Table 1-4: Largest Vaccine Manufacturers
CHAPTER TWO: THE VACCINE INDUSTRY: TRENDS, MAJOR PLAYERS AND MARKETS

  • Table 2-1: Top Vaccine Sellers, 2011: Revenues in US$ millions

  • Table 2-2: Vaccine-Preventable Diseases, August 2011

  • Table 2-3: World Vaccines Market Manufacturer's Market Shares, 2009

  • Table 2-4: Major Vaccine Merger & Acquisition Activity

  • Table 2-5: Vaccines Approved by FDA for US Sales, July, 2011

  • Table 2-6: HHS/ BARDA Vaccine Advanced Development Milestones

  • Table 2-7: Documents Required to Determine Eligibility for WHO Prequalification

  • Table 2-8: Private Sector Price versus Negotiated Price For Selected Vaccines (ActHIB, Havrix, Tripedia, Fluarix, FluMist, Twinrix, Afluria, Decavac, MMRII, Zostravix, ENGERIX-B, Ceravix, Gardasil, Prevnar)

  • Figure 2-1: Private Sector Price versus Negotiated Price ( cost in US dollars)

  • Figure 2-2: Discount for Selected Vaccines (ActHIB, Havrix, Tripedia, Fluarix, FluMist, Twinrix, Afluria, Decavac, MMRII, Zostravix, ENGERIX-B, Ceravix, Gardasil, Prevnar)

  • Figure 2-3: Vaccine Companies vs. Traditional Pharma: Production and Sales Costs
CHAPTER THREE: VACCINE PRODUCTION: SPENDING, INNOVATIONS, AND CHALLENGES

  • Figure 3-1: Doses of Vaccine Produced Worldwide, 2010-2015

  • Table 3-1: Vaccine Classes and Associated Industrial Challenges (Oral Polio, Rabies, Acellular pertussis, Pneumococcal, Hepatitis B, Japanese encephalitis)

  • Table 3-2: Production Methods for Common Vaccines (Oral polio, Tetanus, Measles, Influenza, Diphtheria, Pertussis, BCG, Hep. B, Hib, MMR)

  • Table 3-3: Inactivated or Attenuated Vaccine Examples

  • Table 3-4: Acelluar/Component Vaccine Examples

  • Table 3-5: Attenuated Vaccine Examples

  • Table 3-6: Toxoid Vaccine Examples

  • Table 3-7: Thiomersal Content of Vaccines Routinely Recommended for Children

  • Table 3-8: Preservatives Used in U.S. Licensed Vaccines

  • Table 3-9: Annual Influenza Statistics

  • Table 3-10: Cell-based Vaccine Advantages

  • Table 3-11: Activities at WHO Collaborating Centers

  • Table 3-12: Activities at Vaccine Manufacturers

  • Figure 3-1: Vaccine Approval Timeline

  • Table 3-13: Advantages of Cell Culture Vaccines

  • Figure 3-2: Spending on Vaccine Production, Estimated (2008-2015) (billions of US Dollars Spent)

  • Table 3-14: Top Vaccine Contract Manufacturers, 2011

  • Figure 3-3: Estimated Outsourcing Market for Vaccines (2008-2015)